Key Points
This could mark a new era for Alzheimer's treatment as the FDA grants full approval to a promising new drug called 'Lecanemab.' The drug is being sold by Eisai under the brand name 'Leqembi.'AP..
Aducanemab (brand name Aduhelm), once hoped to be a breakthrough, received 'accelerated approval' from the FDA but reported disappointing clinical trial results...
New clinical trial results for another Alzheimer's drug called 'donanemab' are also expected in the next few weeks..
Lecanemab cannot cure Alzheimer's disease, but it has reportedly proven to slow down the loss of cognitive function..
In a clinical trial involving 1,800 patients, Lecanemab was found to slow cognitive decline by an average of 27% over 18 months...
You might be interested in
FDA endorses Lecanemab: Breakthrough Alzheimer's treatment offers hope for many
13, Jun, 23Groundbreaking Alzheimer's treatment, lecanemab, receives FDA panel endorsement. Clinical trials show promising results | World News
Donanemab raises hopes for treatment of Alzheimer’s. What is it?
19, Jul, 23A new drug called Donanemab has become a turning point in treating Alzheimer’s disease.
Explainer: Who is eligible for the new FDA-approved Alzheimer's drug?
07, Jul, 23The U.S. Food and Drug Administration on Thursday granted standard approval to Eisai (4523.T) and Biogen's (BIIB.O) Leqembi for patients with Alzheimer's disease.
Highly awaited Lilly's Alzheimer's drug hit by delays
08, Mar, 24Donanemab has been found to slow cognitive decline in the early stages of the disease during a clinical trial.